FDA grants accelerated approval for AstraZeneca breast cancer treatment
The Food and Drug Administration granted accelerated approval for AstraZeneca’s Etcamah (camizestrant) in combination with a CDK4/6 inhibitor to treat eligible advanced breast cancer patients.
Story updates
10:10:15 PM UTC
SquawkNews
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic bre…
10:33:23 PM UTC
SquawkNews
FDA Approves AstraZeneca Treatment for Advanced Breast Cancer — Update
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S.
Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic bre…